Stryker (SYK) Gets a Buy Rating from BTIG

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Stryker (SYKResearch Report), with a price target of $273.00. The company’s shares closed last Thursday at $245.33.

According to, Zimmerman is a 5-star analyst with an average return of 14.9% and a 47.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Zimmer Biomet Holdings, and Organogenesis Holdings.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Stryker with a $295.36 average price target, a 18.2% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $315.00 price target.

See the top stocks recommended by analysts >>

Based on Stryker’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $4.16 billion and net profit of $438 million. In comparison, last year the company earned revenue of $3.74 billion and had a net profit of $621 million.

Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.

Read More on SYK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More